Leerink downgraded BioMarin (BMRN) to Market Perform from Outperform with a $60 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin downgraded to Hold at Stifel on Voxzogo concerns
- BioMarin downgraded to Hold from Buy at Stifel
- BioMarin price target lowered to $88 from $95 at Bernstein
- BioMarin: FDA accepts for Priority Review sBLA for Palynziq
- Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth